• Ivermectin in Modern Parasitology and Tumor Microenvironment

  2026-07-15

  Explore how Ivermectin, a broad-spectrum anti-parasitic compound, is redefining advanced parasitology research and contributing to our understanding of tumor microenvironments. This article delivers unique scientific insights, protocol guidance, and connects recent breakthroughs in Gasdermin C biology to experimental design.

• Ivermectin’s Mechanistic Edge in Translational Parasitology

  2026-07-15

  This thought-leadership article explores how Ivermectin’s well-characterized neuromuscular mechanism enables strategic advances in anti-parasitic research and translational drug development. By synthesizing mechanistic insight with workflow guidance, and drawing purposeful parallels to recent oncology breakthroughs, it offers translational researchers a blueprint for rigorous, cross-domain discovery—anchored by APExBIO’s product integrity.

• Tofacitinib (CP-690550) Workflows for Immune Modulation Rese

  2026-07-14

  Tofacitinib (CP-690550) enables researchers to precisely inhibit JAK/STAT signaling in immune cell assays, offering unique advantages for dissecting cytokine-driven inflammation and metabolic dysfunction. This article translates the latest mechanistic findings and workflow optimizations into practical guidance for maximizing reproducibility and insight when studying immune modulation with APExBIO’s Tofacitinib.

• SM-102: Ionizable Lipid for mRNA Vaccine Delivery Systems

  2026-07-14

  SM-102 is a synthetic lipid, heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate, critical for lipid nanoparticle (LNP) mRNA delivery. Its use facilitates efficient mRNA uptake and endosomal escape, and recent computational studies benchmark its efficacy versus other ionizable lipids.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Axis Modul

  2026-07-13

  A recent study demonstrates that gramine, a natural indole alkaloid, suppresses the growth of triple-negative breast cancer (TNBC) cells by triggering ferroptosis through the CUL3-mediated regulation of MTDH. This mechanistic insight highlights the CUL3–MTDH axis as a novel therapeutic target and suggests gramine’s translational potential for aggressive breast cancers.

• Spiroplasma eriocheiris Entry Pathways in Drosophila S2 Cell

  2026-07-13

  This study reveals that Spiroplasma eriocheiris invades Drosophila Schneider 2 (S2) cells primarily via clathrin-mediated endocytosis and macropinocytosis, not through caveola-dependent routes. The research provides a mechanistic basis for understanding Spiroplasma-host interactions and sets a precedent for using invertebrate cell models to dissect pathogen entry strategies.

• Puromycin Aminonucleoside: Strategic Innovation in Podocyte

  2026-07-12

  This thought-leadership article deciphers the mechanistic underpinnings and translational strategy behind puromycin aminonucleoside, the aminonucleoside moiety of puromycin, as the gold standard for modeling podocyte injury and nephrotic syndrome. Building upon recent advances in glomerular lesion induction and the evolving clinical landscape, we bridge experimental insight with guidance for translational researchers aiming to optimize protocol design, harness emerging biomarkers, and drive innovation in renal pathology research. The discussion draws on the latest literature, including parallels between podocyte injury and EMT regulatory pathways, and offers a forward-looking outlook on biomarker discovery and therapeutic strategies.

• RapaLink-1: Redefining mTOR Inhibition for Dormancy & Cancer

  2026-07-10

  Discover how RapaLink-1, a third-generation mTOR inhibitor, enables precise control over mTORC1-driven dormancy and cancer growth. This article delivers in-depth analysis and actionable protocol guidance, setting it apart from existing reviews.

• Deferasirox Fe3+ Chelate in Iron Overload Research: Practica

  2026-07-09

  Explore how Deferasirox Fe3+ chelate (SKU A3355) addresses core challenges in iron overload treatment research, from protocol optimization to vendor selection. This article synthesizes scenario-based guidance for reliable ferric iron chelation studies, emphasizing evidence-backed workflow choices.

• 8-Chloroadenosine: Precision Disruption of lncRNA-IL-6 Axes

  2026-07-09

  Explore how 8-Chloroadenosine, a powerful nucleoside analog, enables targeted manipulation of lncRNA-driven IL-6 regulation in non-small cell lung cancer research. This article uniquely bridges molecular mechanism with practical assay design for advanced transcriptional regulation studies.

• Dasatinib (BMS-354825): Precision Tools for Kinase-Driven Ca

  2026-07-08

  Discover how Dasatinib (BMS-354825) empowers researchers to unravel kinase signaling and therapeutic resistance in cancer biology with nanomolar precision. This article provides a unique deep dive into practical assay design, integrating recent mechanistic insights and advanced applications distinct from standard protocols.

• Ivermectin as a Broad-Spectrum Anti-Parasitic in Advanced Re

  2026-07-08

  Ivermectin stands out as a high-purity, broad-spectrum anti-parasitic research compound for experimental protocols requiring robust, reproducible performance. Its precise use in parasitology and translational models enables nuanced investigation of drug mechanisms and host–pathogen interactions.

• RapaLink-1: Precision Control of mTOR for Dormancy and Oncol

  2026-07-07

  Explore how RapaLink-1, a third-generation mTOR inhibitor, enables precise and robust control of mTOR pathways for both embryonic dormancy research and cancer models. This article delivers advanced insights into protocol design, resistance mutation targeting, and practical assay optimization.

• Patient-Derived Gastric Cancer Assembloid Model: Tumor–Strom

  2026-07-07

  This study presents a novel patient-derived gastric cancer assembloid system that integrates matched tumor organoids with stromal subpopulations, closely mimicking the tumor microenvironment. The model provides new opportunities to study tumor–stroma interactions, drug response variability, and resistance mechanisms, advancing the field of personalized preclinical cancer research.

• Allosteric PDK4 Inhibitors: New Scaffolds for Metabolic Dise

  2026-07-06

  The referenced study identifies and characterizes a novel class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with compound 8c demonstrating potent in vitro and in vivo efficacy against metabolic, allergic, and proliferative disease models. These findings provide a validated scaffold for further drug discovery and highlight the therapeutic value of targeting metabolic regulation in disease.

432 records 10/29 page Previous Next First page 上5页 678910 下5页 Last page